Softox — Trading Ideas on TradingView

SOFTOX $SOFTX HAS COMPLETED ENROLMENT INTO #SWIS STUDY SOFTOX HAS COMPLETED ENROLMENT OF SOFTOX WOUND IRRIGATION SOLUTION CONFIRMATORY STUDY (SWIS-02) SoftOx Solutions AS ("SoftOx") is pleased to announce that the enrolment of study participants for the clinical investigation «SWIS-02» has been completed. The study, which has been conducted at Bispebjerg University Hospital is a confirmatory clinical investigation to document safety and performance of SoftOx Wound Irrigation Solution ("SWIS") compared to Normal Saline (NS) in a human wound model. It is a confirmative study and last of two clinical studies on "SWIS". We are very pleased to have completed this enrolment because of the ongoing lockdown in Denmark, which were affecting our recruitment pace. "With this pivotal trial we are eagerly looking forward to examining and analyse the study data and report on the results later in Q2-2021", says Glenn Gundersen, Medical Director of SoftOx. SWIS is under development to become a medical device intended for wound rinsing and moistening to prevent infections in all types of acute wounds, such as abrasions, cuts, burns and surgical wounds.

#Softox $SOFTX rally after Kinderegg of great recent news * Retail distribution agreement for Nordics and UK with Norgesgruppen * Successfull private offering on NOK 55 securing a good cash position to see company through to positive cash flow * Enthustiastic Danish coverage of successfull animal experiments for antiviral inhalation treatment "Possible game changer, says University of Copenhagen" Comes on top of previous news that the company received a 2 milln USD grant from the United States defence for their wound treatment product

SoftOx Infection remover - US Department of Defense (DoD) grant SoftOx, today announced the US Department of Defense (DoD) awarded SoftOx $1.977 million (USD) for research and development of the SoftOx Infection remover (Biofilm Eradicator). Oslo 03.11.2020 The project is a research and development collaboration between SoftOx Solutions AS and leading US and European wound care clinics, focusing on chronic wounds and biofilm infections. The project represents an innovative treatment principle in how to prevent and treat biofilm infections in wounds. The grant will contribute to perform clinical investigations to evaluate the SoftOx technology in humans with serious non-healing wounds. The award was issued on behalf of the Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) a biomedical technology consortium that collaborates under a transaction agreement (OTA) with the US Army Medical Research and Development Command (USAMRDC). The award issued is entitled “Clinical Development of a New Antimicrobial Agent to Treat and Prevent Biofilm Formation in Wounds”. SoftOx considers it a great honor that one of the world’s leading research organizations supports the development and the technology of SoftOx by issuing the award. About SoftOx Solutions SoftOx Solutions AS (SoftOx, listed at Oslo Stock Exchange Merkur Market) is a Norwegian MedTech company based in Oslo with the aim to contribute to fight major threats to human health, namely; the Emergence of Antimicrobial Resistance (AMR), Biofilm Infections in Chronic Wounds and Spread of viruses. For more information about SoftOx please visit www.soft-ox.com About Medical Technology Enterprise Consortium MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command. To find out more about MTEC, visit www.mtec-sc.org.

Softox promising consolidation above 50 SMA Look for the stock punching through 200 SMA on good volume

#SoftOx closer to a possible breakthrough against #covid19 The Danish Medicines Agency has given its recommendation for further development of the SoftOx inhalation solution for the treatment of respiratory infections, including COVID-19. The SoftOx Inhalation Project aims to develop an inhalation solution for the treatment of respiratory infections. This has the potential to be a breakthrough in the treatment of respiratory infections including Covid-19 infections. Following a scientific advisory meeting with the Danish Medicines Agency, a favorable development path has been suggested to be able to start testing in humans as soon as possible. - It is now expected that the first studies in humans can start as early as the second quarter of 2021. SoftOx will therefore immediately start preparations to provide the necessary documentation that involves further safety studies in animal models, says Geir Almås, CEO of SoftOx Solutions. - The need for new solutions treating respiratory tract infections is significant, this is a market which with conservative estimates for the EU and the US is approximately 12 billion USD. The number can probably be doubled looking in a global perspective, continue Almås. This technology is unique, it is simple, exceptionally effective and does not trigger resistance. The effect is also independent of possible new mutated variants, as recently reported for the Corona virus. - My team and I believe that we are facing a breakthrough in the treatment of difficult infections, both viral and bacterial. We have tested SoftOx solutions in the respiratory tract and we see that this can be an important treatment principle that can help fight the ongoing pandemic and future epidemics and pandemics ", says Professor of Microbiology and trial leader Thomas Bjarnsholt at the University of Copenhagen. For more information contact: Professor Thomas Bjarnsholt; [email protected] +45 206 59 888 CEO Geir Almås; [email protected] +47 977 59 071 Professor Thomas Bjarnsholt is a member of the company's Scientific Advisory Board and has 20.000 stock options in SoftOx Solutions.